Literature DB >> 8097224

Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-gamma production.

S E Macatonia1, T M Doherty, S C Knight, A O'Garra.   

Abstract

IL-10 has previously been shown to inhibit cytokine production by Th1 cells by blocking macrophage accessory cell function. In this study we demonstrate that dendritic cell-induced Th1 proliferation was unaffected by IL-10, whereas macrophage-stimulated proliferation was inhibited in the same system. In contrast dendritic cell induced IFN-gamma production by the Th1 clones was down-regulated by IL-10. Inasmuch as dendritic cells have been shown to be potent APC for T cells in primary responses we determined the effect of IL-10 on dendritic cell-induced proliferation and IFN-gamma production by CD4+ and CD8+ T cells. Dendritic cells were effective at stimulating both proliferation and IFN-gamma secretion of CD4+ or CD8+ T cells in a primary allogeneic mixed leukocyte response. In contrast, IL-10 markedly inhibited dendritic cell driven IFN-gamma production by purified CD4+ and CD8+ T cells. Down-regulation of dendritic cell-induced IFN-gamma production suggests a role for IL-10 in inhibiting the initiation of cell-mediated immune responses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097224

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

1.  IL-10 enhances IL-2-induced proliferation and cytotoxicity by human intestinal lymphocytes.

Authors:  E C Ebert
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

Review 2.  Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease.

Authors:  S T Azar; H Tamim; H N Beyhum; M Z Habbal; W Y Almawi
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  Regulatory function of in vivo anergized CD4(+) T cells.

Authors:  K Jooss; B Gjata; O Danos; H von Boehmer; A Sarukhan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  T lymphocyte immunity in host defence against Chlamydia trachomatis and its implication for vaccine development.

Authors:  X Yang; R Brunham
Journal:  Can J Infect Dis       Date:  1998-03

Review 5.  Current status of gene delivery and gene therapy in lacrimal gland using viral vectors.

Authors:  Shivaram Selvam; Padmaja B Thomas; Sarah F Hamm-Alvarez; Joel E Schechter; Douglas Stevenson; Austin K Mircheff; Melvin D Trousdale
Journal:  Adv Drug Deliv Rev       Date:  2006-09-15       Impact factor: 15.470

6.  Rapid development of severe hyperplastic gastritis with gastric epithelial dedifferentiation in Helicobacter felis-infected IL-10(-/-) mice.

Authors:  D J Berg; N A Lynch; R G Lynch; D M Lauricella
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

7.  Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity.

Authors:  Tanja Schreiber; Stefan Ehlers; Lisa Heitmann; Alexandra Rausch; Jörg Mages; Peter J Murray; Roland Lang; Christoph Hölscher
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

8.  Combinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheres.

Authors:  Jamal S Lewis; Chris Roche; Ying Zhang; Todd M Brusko; Clive H Wasserfall; Mark Atkinson; Michael J Clare-Salzler; Benjamin G Keselowsky
Journal:  J Mater Chem B       Date:  2014-05-07       Impact factor: 6.331

9.  Treatment with anti-interleukin-10 monoclonal antibody enhances early resistance to but impairs complete clearance of Listeria monocytogenes infection in mice.

Authors:  R D Wagner; N M Maroushek; J F Brown; C J Czuprynski
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

Review 10.  The enhancement of arbovirus transmission and disease by mosquito saliva is associated with modulation of the host immune response.

Authors:  Bradley S Schneider; Stephen Higgs
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-03-14       Impact factor: 2.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.